← Leaderboards
Gildon N Beall
La Biomed Res Inst/ Harbor Ucla Med Ctr
$1,671,738
Attributed
$1,671,738
Total exposure
8
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,671,738 · 8
By mechanism
M01$1,671,738 · 8
Top collaborators
No co-investigators on record.
Most similar at La Biomed Res Inst/ Harbor Ucla Med Ctr
Same institution · by research overlap
- Shalendar Bhasin$66,433,688
- Richard Casaburi$5,363,085
- Margaret A Keller$2,116,833
- Eric S Daar$9,910,615
- Christina C. Wang$7,924,844
Others in their field
Top investigators on “Hiv Infections”
- Wafaa M. El-Sadr · Columbia University Health Sciences$965,259,079
- Lawrence Corey · Fred Hutchinson Cancer Center$728,701,834
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$467,263,656
- Judith S. Currier · University Of California Los Angeles$466,447,923
- Richard Marlink · Elizabeth Glaser Pediatric Aids Fdn$457,210,249
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
Research focus
Hiv InfectionsHuman SubjectClinical ResearchHuman Therapy EvaluationAids TherapyCombination ChemotherapyProtease InhibitorTestosteroneAntiaids AgentDrug Screening /EvaluationHormone TherapyFemaleReverse Transcriptase InhibitorsDrug Administration RoutesImmunotherapyInterleukin 2Intravenous AdministrationMuscle StrengthOutcomes ResearchRecombinant ProteinsHelper T LymphocyteWeight LossMetabolismHuman Immunodeficiency Virus
Grant awards (23)
PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED$237,978
M01 · FY2001 · RR
TESTOSTERONE REPLACEMENT AND RESISTANCE EXERCISE IN HIV WASTING SYNDROME$237,978
M01 · FY2001 · RR
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART$237,978
M01 · FY2001 · RR
ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT$237,978
M01 · FY2001 · RR
ACTG398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN COM$237,978
M01 · FY2001 · RR
PHARMACOKINETICS OF TESTOSTERONE MATRIX TRANSDERMAL SYSTEM IN HIV INF$237,978
M01 · FY2001 · RR
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN$237,978
M01 · FY2001 · RR
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART$982
M01 · FY2000 · RR
PHARMACOKINETICS OF TESTOSTERONE MATRIX TRANSDERMAL SYSTEM IN HIV INF$982
M01 · FY2000 · RR
PHASE I/II DOSING SAFETY AND ANTIVIRAL ACTIVITY OF HYDROSYUREA ALONE/COMBINED$982
M01 · FY2000 · RR
ACTG388 EFAVIRENZ OR NELFINAVIR IN COMBINATION W/ FIXED DOSE COMBINAT$982
M01 · FY2000 · RR
ACTG398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN COM$982
M01 · FY2000 · RR
TESTOSTERONE REPLACEMENT AND RESISTANCE EXERCISE IN HIV WASTING SYNDROME$982
M01 · FY2000 · RR
ACTG384--Protease inhibitor/reverse transcriptase inhibitor in initial HIV therap$0
M01 · FY2000 · RR
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART$0
M01 · FY2000 · RR
ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART$0
M01 · FY2000 · RR
ACTG398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN COM$0
M01 · FY2000 · RR
ACTG398 AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR REGIMENS IN COM$0
M01 · FY2000 · RR
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN$0
M01 · FY2000 · RR
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN$0
M01 · FY2000 · RR
PHYSIOLOGIC TESTOSTERONE REPLACEMENT IN HIV INFECTED WOMEN$0
M01 · FY2000 · RR
ACTG384--Protease inhibitor/reverse transcriptase inhibitor in initial HIV therap$0
M01 · FY2000 · RR
ACTG384--Protease inhibitor/reverse transcriptase inhibitor in initial HIV therap$0
M01 · FY2000 · RR